Checkpoint Inhibitors and SBRT for MCRPC

Summary

The goal of this investigator-initiated, single-center, and randomized phase II trial is to investigate the potential synergistic effect of combining stereotactic body radiotherapy of a single soft tissue- or bone metastasis with ipilimumab and nivolumab in patients with mCRPC and perform translational analyses on tissue and blood, searching for predictive biomarkers of efficacy and toxicity. Participants will be randomized to receive ipilimumab and nivolumab with or without stereotactic body radiotherapy (SBRT).

Timeline

Start

2019-11-25

Primary completion

2024-08-30

Completion

2024-08-30

Publications

• Spindler NJ, Persson GF, Theile S, Nielsen DL, Hogdall EV, Al-Farra G, Hendel HW, Lorentzen T, Svane IM, Lindberg H, Eefsen RL. Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol. BMJ Open. 2023 Jan 30;13(1):e063500. doi: 10.1136/bmjopen-2022-063500.

Drugs

Indications